Allison is Founder/CEO of HNF brings a unique perspective to research as a patient, caregiver and advocate . She provides a wealth of leadership experience as PI on the patient registry, Global Registy for Inherited Neuropathies (GRIN), two Patient Clinical Outcomes Research Institute (PCORI) grants, a NIH CDC grant, the El-PFDD meeting for FDA and now the lead of the first ever CMT biobank. Allison’s passion for optimizing CMT research and trials led her to develop the Therapeutic Research in Accelerated Discovery (TRIAD) bringing academia, industry and government together to achieve results. HNF continues to build a global research consortium of patients, researchers, and industry to further advance natural history studies, biomarkers, and the development of digital and video outcome measures to support therapy development and the regulatory path to successful IND’s and clinical trials. She has spoken at Global Genes RARE Summit, FDA El-PFDD Meeting, MDA Conference, Peripheral Nerve Society, Quest Diagnostics, AANEM, and more.